Legal Entity
Insights
LION THERAPEUTICS PTE. LTD.
Last Updated: 17 Jun 2026
Lion TCR develops personalized T cell receptor (TCR‑T) immunotherapies to eliminate Hepatitis B virus (HBV)-related hepatocellular carcinoma and to treat viral infections prevalent in Asia. The company maintains the largest patented HBV-specific TCR library covering roughly 80% of patient HLA types, employs mRNA-delivered transient TCR expression for enhanced safety, and operates a state-of-the-art GMP facility to manufacture autologous and allogeneic TCR‑T products. Lion TCR’s lead programs have demonstrated proven clinical safety and an approximately three-fold increase in survival versus standard of care in Phase 1 studies, and the company is actively advancing clinical trials, regulatory approvals, research collaborations, and financing to expand its pipeline.
Country of registration | Singapore |
Registration number | 201538294N |
Local SIC | |
Incorporation date | 21 Oct 2015 |
Company age | 10 years 8 months |
Official entity type | Private Limited Company |
No. of officers | 76 |
Contact
Address:
77 AYER RAJAH CRESCENT, #01-29, Singapore 139954
Access Key Decision Makers
This is the legal entity page of LION THERAPEUTICS PTE. LTD.. To access company info, company size, news , key makers’ emails, visit the profile pages above.
Associated business (1)
- LION TCRView MoreSingaporeLion TCR develops personalized T cell receptor (TCR‑T) immunotherapies to eliminate Hepatitis B virus (HBV)-related hepatocellular carcinoma and to treat viral infections prevalent in Asia. The company maintains the largest patented HBV-specific TCR library covering roughly 80% of patient HLA types, employs mRNA-delivered transient TCR expression for enhanced safety, and operates a state-of-the-art GMP facility to manufacture autologous and allogeneic TCR‑T products. Lion TCR’s lead programs have demonstrated proven clinical safety and an approximately three-fold increase in survival versus standard of care in Phase 1 studies, and the company is actively advancing clinical trials, regulatory approvals, research collaborations, and financing to expand its pipeline.
This is the legal entity page of LION THERAPEUTICS PTE. LTD.. To access company info, company size, news, key maker's emails, visit the profile pages above.
Financials
Revenue | < 1m |
Share Capital - Ordinary shares | SGD 4,392,664 |
Last updated: 17 Jun 2026
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Discover More Companies
Lookalike companies
* This profile contains information from ACRA Information on Corporate Entities from Accounting and Corporate Regulatory Authority which is made available under the terms of the Singapore Open Data Licence version 1.0. Information and datasets on our website are provided on an “as is” and “as available” basis. This website makes no representations or warranties concerning the datasets, including but not limited to any representation or warranty as to the accuracy, completeness, reliability, continued availability, timeliness, non-infringement, title, quality, or fitness for any particular purpose of the datasets to the fullest extent permitted by the law.
Frequently Asked Questions (FAQ)
- What is the address of LION THERAPEUTICS PTE. LTD.?
- Where is LION THERAPEUTICS PTE. LTD.'s headquarter?
- What is LION THERAPEUTICS PTE. LTD.'s contact number?
- What LION THERAPEUTICS PTE. LTD.'s spending power?
- Does LION THERAPEUTICS PTE. LTD. have a presence in the domain it operates in?